Clinical Trial Search

Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9

Primary: Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16 — 18.567; -4.113 wood units*meter^2

Primary: Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population — 6.44; 13.40; 10.58; 10.24 percent change — p=0.056

Primary: Participants >=2 Years of Age: Observed Steady-State Trough (Pre-dose) Plasma Concentration of Macitentan and Aprocitentan (Active Metabolite) at Week 12 Based on Body…

Primary: Number of Participants Reporting at Least One Adverse Event — 41; 55; 73; 13 Participants

Primary: Dose-corrected Daily Exposure [AUC(0-24c)] to Bosentan — 7275.1; 8535.4 h*ng/mL

Primary: Population Pharmacokinetics: Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau) for Tadalafil — 8170; 8390; 15200; 4550…

Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04

Primary: Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters — 36.60; 60.48 Meters

Primary: Number of Participants With Successful Transition From IV/SC Remodulin to Oral Treprostinil (Cohort 1), From Inhaled Prostacyclin to Oral Treprostinil (Cohort 2), or as…

Primary: Transthoracic Echocardiogram (ECHO)-Based Change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) Measurement — 2.244; 2.244; 2.300; 2.212 mm

Primary: Change From Baseline to End of Study (EOS) in Height for Age. — -0.8; 0.32; -0.64; -0.74 Z-score

Primary: Area Under the Curve for Ambrisentan Plasma Concentration — 7871.46 ng*hr/mL

Primary: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 8; 8; 2 participants

Primary: Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks — 1.28 mL/min/kg

Primary: Fold Change From Baseline at Week 24 in Pulmonary Vascular Resistance Index (PVRI) — 59.43 Fold change (percentage)

Primary: Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) — 3; 13; 5; 10 Participants

Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883

Primary: Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core — 27; 29; 3; 3 participants

Primary: Pulmonary Vascular Resistance (PVR) — 6.7 woods unit

Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) — 514.6; 512.0 dyn*sec/cm^5 — p=0.0220

Primary: Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks — -27.6; -168.4; -258.9; 802.0 dynes*sec/cm^5 — p=0.0030

Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC) — 35; -28; -21; 6 dyne*sec/cm^5 — p== 0.214

Primary: Change in Pulmonary Vascular Resistance — 7.1 percent difference from baseline

Primary: Changes From Baseline in Peak Exercise Mean Pulmonary Artery Pressure (mPAP), Transpulmonary Pressure Gradient (TPG), and Pulmonary Capillary Wedge Pressure (PCWP)…

Primary: Plasma Estradiol (E2) Level — -40; -4 % change from baseline

Primary: Maximum Sildenafil Plasma Concentration — 181; 515; 545; 202 ng/mL

Primary: Change in Mean Pulmonary Artery Pressure (MPAP) — 6.5; 4.3 mmHg

Primary: Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12) — -20.70; -20.20 mmHg

Primary: Relative Change From Baseline to Week 12 in Pulmonary Vascular Resistance (PVR). — 0.63; 0.98 ratio — p=0.0001